Physician profile
Michael J Palazzo
NPI 1699902957
$62,703.79
in general payments reported to CMS, 2019-2025
15 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,913 · 2022: $3,745 · 2023: $14K · 2024: $19K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $12K · Travel and Lodging: $3,363 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,483.00 |
| Food and Beverage | $11,992.70 |
| Travel and Lodging | $3,362.80 |
| Education | $207.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $48,579.39 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $3,006.53 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $2,021.99 | 2021-2025 | Ingrezza |
| Indivior INC. | $1,849.79 | 2022-2024 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $1,591.66 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,492.21 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,365.31 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,269.91 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $626.14 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $353.12 | 2022-2024 | Abilify Asimtufii |
| Janssen Scientific Affairs, LLC | $299.03 | 2022-2025 | Invega Sustenna |
| Lundbeck LLC | $137.82 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $44.43 | 2025 | Fanapt |
| Intuitive Surgical, INC. | $41.72 | 2024 | |
| Avanir Pharmaceuticals, INC. | $24.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Palazzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.